Daré Bioscience Publishes Positive Phase 1 Data for Sildenafil Cream in Postmenopausal Women — Daré Bioscience, Inc.

Event summary

Daré Bioscience published Phase 1 clinical trial results for its proprietary sildenafil cream in Menopause - The Journal of The Menopause Society.
The study found all evaluated doses of the cream were well tolerated with minimal systemic exposure in postmenopausal women.
The company plans to commence prescription dispensing and initial product revenue for DARE to PLAY Sildenafil Cream in Q3 2026.
Daré is pursuing FDA approval via the 505(b)(2) regulatory pathway for its proprietary formulation.

The big picture

Daré Bioscience is addressing a significant gap in women's health with its sildenafil cream formulation, targeting female sexual arousal disorder which currently lacks FDA-approved treatments. The company's strategy combines immediate market access through compounding with a long-term play for FDA approval, positioning itself in an underserved segment of the women's health market. The positive Phase 1 results reinforce the potential of this approach, though execution risks remain in both regulatory and commercialization efforts.

What we're watching

Regulatory Pathway: Whether Daré can successfully navigate the FDA's 505(b)(2) pathway for its proprietary sildenafil cream.
Market Acceptance: The pace at which DARE to PLAY Sildenafil Cream gains market acceptance through the 503B compounding route.
Competitive Positioning: How Daré's dual strategy of pursuing FDA approval while offering a compounded version will affect its competitive positioning.